MedPath

Evaluation of Diprospan Injection to the Knee on Rehabilitation of Patients After TKR of the Contralateral Knee

Phase 4
Completed
Conditions
Osteoarthritis
Interventions
Drug: Bupivocaine
Drug: Betamethasone
Registration Number
NCT00542139
Lead Sponsor
Hadassah Medical Organization
Brief Summary

This study is performed to assess the influence of intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate) into osteoarthritic knee in patients who undergo a total knee replacement of their contralateral knee.

The study population will include 50 patients with bilateral knee osteoarthritis, admitted for their first knee replacement surgery. Only patients with older than 50 years with primary osteoarthritis will be included. The patients will be randomized into 2 groups. Intervention group will receive an injection of 2ml Diprospan diluted in 10 ml Bupivocaine. The control group will receive an injection of 10ml of Bupivocaine. All patients will be followed after 6 weeks and three functional rehabilitation and pain scores will be assessed (VAS pain score, Timed Up and Go Score and Functional Ambulatory Category Scale).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Age older than 50
  • Bilateral primary knee osteoarthritis
  • Undergoing knee arthroplasty
Read More
Exclusion Criteria
  • Active infection
  • Allergy to medication compounds
  • Pregnancy
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2Bupivocaine-
1Betamethasone-
Primary Outcome Measures
NameTimeMethod
Visual analogue pain score6 weeks
Secondary Outcome Measures
NameTimeMethod
Timed Up and Go Score6 weeks
Functional Ambulatory Category Scale6 weeks

Trial Locations

Locations (1)

Hadassah Medical Organization

🇮🇱

Jerusalem, Israel

© Copyright 2025. All Rights Reserved by MedPath